% | $
Quotes you view appear here for quick access.

InVivo Therapeutics Corp Message Board

  • garcia_invest garcia_invest Nov 30, 2011 10:47 AM Flag

    $10 Billion Market

    Watch the CEO speak on the website. They can manufacture their device and take it to market as soon as FDA approves them to. This is a $10 billion market. Even at say $1.5 Billion market cap, this stock is at $20 a share.

    Ok, lets cut that in half for dilution of the shares, that is still $10 a share.

    There is nothing better than a CEO benefiting from the approval form the FDA. Plus they are in located in Boston area, home of Biotechs. Worst possible outcome they get bought out for $7 share.

    Right now the stock price is saying the market is only $20 million.

    You can be sure by the end of 2013 this stock will be in the $10-15 range. That is 5 times your money!!!

    Stay strong and don't get shaken out.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • bumpmeister May 4, 2012 10:53 AM Flag


    • Looks to be much bigger market than $10 billion after you add in all the other applications in the pipe.

      • 1 Reply to tempabear
      • The injectable hydrogel market alone is $15 billion!!

        We see an enormous opportunity for the injectable hydrogel. The acute and chronic spinal cord injury market is estimated at $20 to $25 billion in the U.S. alone. For peripheral nerve pain, there are an estimated 3.2 million nerve block injections done in the U.S. each year. It's an estimated $15 billion market. Existing treatment options are limited and only curb pain for as little as one week. A localized injection using the hydrogel to provide time-released anti-inflammatory therapies like methylprednisolone could provide pain relief for up to twelve months with limited systemic side-effects.

    • >>Anyway, maybe someone here can answer this. Wouldn't they be able to take someone already paralyzed, cut away the scar tissue,implant their scaffold and achieve benefits?<<

      Frank Reynolds said in his presentations that that is what they hope to do with the scaffold plus cells in the future. However they will need to work their way up through fresh injuries before they try cronic cases. I personally think that may be stretching the possibilities since axons would need to grow through the old injury site and extend out to the periferal nervous system downstream of the injury.


    • Garcia - I am not a doctor but everything I have read indicates that there is a fairly short window of opportunity where the surgery and implant can do the most good. But who knows as technology continues to progress there may be more hope for longer term paralysis. I guess that's why many of us are here investing in such technology. Actually what has already been achieved by Invivo is nothing short of a miracle in itself in my book. If the FDA fails to see this it is a real sad state of affair. The new guidelines for device approval should give them an excellent chance plus the FDA now has to fully provide reasons and exactly what is needed. Since there has been correspondence back and forth since June of 2011 on the ind I would think that whatever hurdles came up have been addressed but we must wait and see.

    • The scientists all have very impressive bios with a lot of connections, even with the FDA. (hopefully that is an advantage)

      Anyway, maybe someone here can answer this. Wouldn't they be able to take someone already paralyzed, cut away the scar tissue,implant their scaffold and achieve benefits?

      I'm guessing that it would depend on the type of injury and amount of atrophy, but seems like it would be doable.

      Any doctors in the house?


    • Last couple of days is a buyer's gift! Last chance to get NVIV this cheap, IMO.

    • And folks... the $10 Billion is merely the spinal market. There's peripheral applications, brain applications, eye applications, not to mention other organ systems. The hydrogel combined with stem cells will be revolutionary. It could grow to a $100 Billion industry eventually. Imagine "3D Printing in repair of organs" eventually coming into play? isn't an $85 stock because it is not your conventional pinksheet (do the research). Once these technologies converge, medicine will be ordering up new organs for folks. NVIV is and will be an increasingly important player in the coming biotech revolution.

    • Keeping the faith! Every day is one step closer.

    • I'd say by the end of 2012